Clinical Trial Update: Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies [Phase 1]

View source ↗

Summary

Phase 1 study evaluating autologous CD19 CAR-T cell therapy SYNCAR-001 with orthogonal IL-2 STK-009 in CD19-positive hematologic malignancies; the trial is curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Indolent B-cell Non-hodgkin Lymphoma
• Mantle Cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• STK-009 (Orthogonal interleukin-2 (IL-2) variant)
• SYNCAR-001

Snippet

Sponsor: Synthekine | Conditions: CLL/SLL, NHL | Phase 1 | Status: ACTIVE_NOT_RECRUITING